Premium
THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE
Author(s) -
Federico M.,
Caballero D.,
Marcheselli L.,
Tarantino V.,
Sarkozy C.,
Lopez Guillermo A.,
Wondergem M.,
Kimby E.,
Rusconi C.,
Zucca E.,
Montoto S.,
Silva M.G.,
Aurer I.,
PaszkiewiczKozik E.,
Cartron G.,
Morschhauser F.,
Alcoceba M.,
Chamuleau M.,
Lockmer S.,
Minoia C.,
Issa D.,
Alonso S.,
Conte L.,
Salles G.,
Coiffier B.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_104
Subject(s) - follicular lymphoma , medicine , lymphoma , rituximab , adverse effect , hematology , cumulative incidence , clinical endpoint , clinical trial , oncology , pediatrics , cohort